gsk1120212
Glioblastoma, IDH-mutant
St. Jude Children's Research HospitalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Glioblastoma, IDH-mutant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Andrew P. Groves | Phase 2 | B |
Safusidenib Nuvation Bio Inc. | Phase 3 | B |
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
Pembrolizumab Mayo Clinic | Phase 2 | CCC |
gi-102 Mayo Clinic | Phase 2 | CCC |
View all 15 →
Same molecule, other indications
gsk1120212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →